Biogen pays $900M to resolve whistleblower's MS kickback suit as competition drags on sales

Just as Biogen’s multiple sclerosis franchise is under serious threat from generics and new competition, the company has decided to pay top dollar to settle a long-running kickback lawsuit centered on the drugs.